Can I read Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial on EtoBox?

Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial by Arash Mowla; Sanaz Boostani; Seyed Ali Dastgheib is a Medicine article available to read on EtoBox.

What is Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial about?

## Introduction: The aim of this study is to evaluate the efficacy of duloxetine augmentation in treatment of resistant obsessive-compulsive disorder (ocd). ## Methods: This augmentation trial was designed as an 8-week randomized controlled, double-blind study. forty-six patients experiencing ocd who had failed to respond to at least 12 weeks of treatment with a selective serotonin reuptake inhibitor (fluoxetine, citalopram, or fluvoxamine) were randomly allocated to receive duloxetine or sertraline plus their current anti-ocd treatment. the yale-brown obsessive compulsive scale (y-bocs) was the primary outcome measure. treatment response was defined as 25% or more decrease in scores of y-bocs. the mean dosage of duloxetine was 44.4 mg/d (range, 20-60 mg/d), and the mean dosage of sertraline was 123.8 mg/d (range, 50-200 mg/d). ## Results: Forty-six patients (24 of 30 in duloxetine group and 22 of 27 in sertraline group) completed the trial. both groups showed improvement during the 8-week study period (mean y-bocs total score at week 8 as compared with baseline: p < 0.001 & p < 0.001) without significant difference (p = 0.861). those receiving duloxetine plus their initial medicat

Who reads Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial?

Author

Arash Mowla; Sanaz Boostani; Seyed Ali Dastgheib

Publisher

Ovid Technologies (Wolters Kluwer Health)

Published

2016

Language

EN

Field

Medicine (Health Sciences)